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Induces Angiogenesis After a
Myocardial Infarction in Mice
Hiroko Fujii, MD, PHD,* Zhuo Sun, MD,* Shu-Hong Li, MD, MSC,* Jun Wu, MD,*
Shafie Fazel, MD, PHD,* Richard D. Weisel, MD,* Harry Rakowski, MD,†
Jonathan Lindner, MD,‡ Ren-Ke Li, MD, PHD*
Toronto, Ontario, Canada; and Portland, Oregon
O B J E C T I V E S This study evaluated the capacity of ultrasound-targeted microbubble destruction
(UTMD) to deliver angiogenic genes, improve perfusion, and recruit progenitor cells after a myocardial
infarction (MI) in mice.
B A C KG ROUND Angiogenic gene therapy after an MI may become a clinically relevant approach
to improve the engraftment of implanted cells if targeted delivery can be accomplished noninvasively.
The UTMD technique uses myocardial contrast echocardiography to target plasmid gene delivery to the
myocardium and features low toxicity, limited immunogenicity, and the potential for repeated application.
METHOD S Empty plasmids (control group) or those containing genes for vascular endothelial
growth factor (VEGF), stem cell factor (SCF), or green ﬂuorescent protein (to visualize gene delivery) were
incubated with perﬂutren lipid microbubbles. The microbubble-deoxyribonucleic acid mixture was
injected intravenously into C57BL/6 mice at 7 days after coronary artery ligation (MI). The UTMD
technique facilitated transgene release into the myocardium. Twenty-one days after MI, myocardial
perfusion and function were assessed by contrast echocardiography. Protein expression was quantiﬁed
by Western blot and enzyme-linked immunosorbent assay. Flow cytometry quantiﬁed progenitor cell
recruitment to the heart. Blood vessel density was evaluated immunohistochemically.
R E S U L T S Green ﬂuorescent protein expression in the infarcted myocardium demonstrated gene
delivery. Myocardial VEGF and SCF levels increased signiﬁcantly in the respective groups (p  0.05). The
physiologic impact of VEGF and SCF gene delivery was conﬁrmed by increased myocardial recruitment of
VEGF receptor 2– and SCF receptor (c-kit)–expressing cells, respectively (p  0.05). Consequently, capillary
and arteriolar density (Factor VIII and alpha-smooth muscle actin staining), myocardial perfusion, and cardiac
function were all enhanced (p  0.01 relative to control group) in recipients of VEGF or SCF.
CONC L U S I O N S Noninvasive UTMD successfully delivered VEGF and SCF genes into the infarcted
heart, increased vascular density, and improved myocardial perfusion and ventricular function. The
UTMD technique may be an ideal method for noninvasive, repeated gene delivery after an MI. (J Am
Coll Cardiol Img 2009;2:869–79) © 2009 by the American College of Cardiology Foundation
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870ell transplantation offers the potential to
restore ventricular function after a myo-
cardial infarction (MI). Unfortunately,
this treatment was less effective in initial
linical trials (1,2) than in pre-clinical animal stud-
es (3), due in part to limited engraftment of the
mplanted cells. Angiogenic gene therapy (4–7)
See page 880
ight enhance the benefits of cell therapy by
reparing the myocardium for cell delivery, but will
equire a clinically effective, noninvasive technique
that allows repeated, targeted delivery. Vi-
ral vectors for gene therapy are associated
with safety concerns (8); for example, viral
proteins elicit an immune response within
the target tissue (8,9) and can cause an
intense inflammatory activation of endo-
thelial cells (10). Nonviral delivery vehi-
cles, including plasmids, avoid these con-
cerns but exhibit lower transfection
efficiency and induce only transient ex-
pression of the gene product (11). How-
ever, we recently demonstrated that
transient up-regulation of vascular endo-
thelial growth factor (VEGF) was asso-
ciated with a prolonged (6 months) in-
crease in vessel density and perfusion
(12).
Ultrasound-targeted microbubble de-
struction (UTMD) provides a noninvasive
method to effectively deliver drugs, pro-
teins, and plasmids to targeted organs
(13,14). UTMD plasmid gene delivery
uses myocardial contrast echocardiography
(MCE) and features low toxicity, limited
immunogenicity, and the potential for re-
peated, targeted application. The current
study evaluated UTMD delivery of plas-
id DNA-containing genes for VEGF and stem
ell factor (SCF) after an MI in mice.
ETHODS
reparation of plasmid DNA solution. Three plasmids
all with cytomegalovirus promoter) were used: pCEP4,
ontaining the VEGF165 gene (human); pcDNA3,
ontaining the SCF gene (murine); and pEGFP-N2,
ontaining the green fluorescent protein (GFP) gene
to determine in vivo transfection efficiency). Empty
e
tein
-
-
-
-
d
llasmid pcDNA3.1 was used as a control group. The slasmid deoxyribonucleic acid (DNA) solution was
repared as described in the Online Appendix.
reparation of microbubble-DNA solution. The
icrobubble-DNA solution (25 l of activated
erflutren lipid microbubbles [DEFINITY, Lan-
heus Medical Imaging, Billerica, Massachusetts],
5 l of phosphate-buffered saline [PBS], and 20
l of DNA solution) was prepared as detailed in the
nline Appendix. Briefly, the microbubbles were
rst activated using a Vialmix (Lantheus Medical
maging) apparatus. Next, the activated micro-
ubbles were diluted with PBS (1:1 ratio). Finally,
he plasmid DNA solution was added to the mix-
ure. The microbubble-DNA solution was incu-
ated in an Eppendorf tube for 20 min with gentle
haking.
n vitro determination of % plasmid DNA associated
ith the microbubbles. The microbubble-DNA so-
ution (prepared using 12 g of plasmid DNA) was
llowed to stand in the Eppendorf tube in a vertical
osition for 30 min after the 20-min incubation in
rder to facilitate separation of the microbubble and
iquid phases. After standing, the solution separated
nto 2 phases: an upper, milky-white layer contain-
ng microbubbles and a lower, clear layer containing
lmost no microbubbles. The quantity of plasmid
NA was measured separately for each layer as
escribed in the Online Appendix, and then the %
f plasmid DNA isolated from the microbubbles in
he milky layer was calculated using the following
ormula: [(DNA in milky layer)/(DNA in milky
ayer  DNA in clear layer)]  100.
nimals. We used female C57BL/6 mice (age 8 to
0 weeks; average mouse body weight 19 to 22 g).
ll animal experimental procedures were approved
y the Animal Care Committee of the Toronto
eneral Research Institute, according to the Guide
or the Care and Use of Laboratory Animals.
I and UTMD. MI was induced in female mice as we
reviously described (15). Seven days later, mice with
n infarct wall length of between 25% and 35% of the
eft ventricular (LV) circumference were randomly
eparated into 4 groups: control group (empty plasmid
NA), VEGF group, SCF group, and GFP group.
ene therapy was administered at 7 days after injury
n order to separate the effect of the gene therapy from
he acute inflammatory response of the host. In each
ouse, the microbubble-DNA solution (prepared us-
ng 0.6 mg of plasmid DNA/kg of mouse body
eight) was infused into the tail vein over a period of
min, immediately after the 20-min incubation. After
he infusion, UTMD was carried out with an AcusonB B R E V I A T I O N S
N D A C R O N YM S
F ejection fraction
AC fractional area chang
FP green fluorescent pro
V left ventricle
VEAd left ventricular end
iastolic area
VEAs left ventricular end
ystolic area
VEDV left ventricular end
iastolic volume
VESV left ventricular end
ystolic volume
CEmyocardial contrast
chocardiography
Imyocardial infarction
BS phosphate-buffered
aline
CF stem cell factor
MA smooth muscle actin
TMD ultrasound-targete
icrobubble destruction
EGF vascular endotheliaequoia C256 system (Siemens Medical Solutions
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871nc., New York, New York). An ultrasound beam
elivered with a 15L8 transducer (8MHz, mechanical
ndex 1.6, depth 2 cm) was directed to the heart
or 20 min in an intermittent mode (1 burst of
ltrasound every 500 ms), and the heart was scanned
epeatedly from base to apex (16). Contrast Pulse
equencing technology (Cadence, Siemens) was used
o detect microbubble destruction.
valuation of myocardial GFP expression. We used a
lasmid containing the gene for GFP to establish
he proof of concept that UTMD can facilitate
ransfection of the plasmid into the heart. To
onfirm gene transfection, cells expressing GFP
ere immunohistochemically identified in hearts
ollected at 5 days after UTMD, using an antibody
gainst GFP. The heart tissue was fixed in 4%
araformaldehyde for 2 days, and then incubated at
°C in an increasing gradient of sucrose (10% and
0% for 1 h each; 30% overnight). The tissue was
hen frozen in optimal cutting temperature Tissue-
ek (Sakura Finetek USA Inc., Torrance, Califor-
ia) and cut into 10 m-thick sections. The sam-
les were fixed in acetone at –20°C for 10 min,
ashed, incubated in 0.05% Triton X-100 in PBS
or 5 min, and then blocked with 1% to 2% bovine
erum albumin and 1% to 2% goat serum in PBS.
ach sample was incubated with anti-GFP anti-
ody (1:200, Alexa Fluor, Molecular Probes, In-
itrogen Canada Inc., Burlington, Ontario, Can-
da) for 1 h at room temperature. After washing,
uclei were stained with Hoechst 33342 (1:100).
he slides were washed twice with PBS (10 min
ach), and representative sections from the infarct,
order zone, and remote (normal) myocardium
ere examined under a confocal microscope. The
order between infarct and remote regions is clearly
dentifiable in fixed myocardial tissue (the infarcted
yocardium appears visibly thinner and paler in
olor than the normal tissue). In the tissue sections,
he infarct and border zone were identified using
ematoxylin and eosin staining for basic histological
tructures on the preceding serial section.
valuation of perfusion using MCE. Myocardial per-
usion was assessed 7 days after MI (before
TMD) and 21 days after MI (14 days after
TMD). A microbubble solution diluted with an
qual volume of PBS (50 l) was infused into the
ail vein, and imaging was performed at the mid-
apillary muscle level with the 15L8 transducer set
t 8 MHz (mechanical index  1.6). The micro-
ubble signal intensities were determined by re-
ording images in an intermittent mode (every 50 to
50 ms pulsing interval until the rise in intensity, (nd then every 550 to 650 ms pulsing interval for
he plateau of intensity). Rise intensity was calcu-
ated (difference between intensities at 50 and 150
s, divided by 150 – 50 ms) as a measure of
yocardial blood flow velocity. In this study, a
50-ms pulsing interval corresponded approxi-
ately to the plateau intensity (17); the anterior
all represented the infarct region, and the poste-
ior wall represented the remote region. The inten-
ity ratio was calculated (signal intensity in the
nterior wall divided by that in the posterior wall) to
stimate myocardial blood flow volume. The data
ere analyzed offline using the digital images.
valuation of cardiac function by echocardiography.
ardiac function was evaluated 7 days after MI
before UTMD) and 21 days after MI (14 days after
TMD). Mice were sedated with ketamine (100
g/kg) and xylazine (10 mg/kg). In each mouse,
chocardiographic images were recorded as previ-
usly described (18) with the 15L8 transducer set at
3 MHz. Left ventricular end-diastolic diameter,
nd-systolic diameter, end-diastolic area (LVEAd),
nd end-systolic area (LVEAs) were measured. Left
entricular end-diastolic volume (LVEDV) and left
entricular end-systolic volume (LVESV) were cal-
ulated using the following formulas: LVEDV 
.047  LVEDd3 and LVESV  1.047 
VEDs3. Percent ejection fraction (%EF) and frac-
ional area change (%FAC) of the LV were calcu-
ated as follows: %EF  [(LVEDV  LVESV)/
VEDV]  100; %FAC  [(LVEAd  LVEAs)/
VEAd]  100 (15,19).
easurement of infarct wall length and thickness. In-
arct wall length and thickness were measured 14 days
fter UTMD using echocardiography and compared
mong VEGF, SCF, and control groups. Briefly,
mages from the B-mode were collected at the LV
hort axis view of the papillary muscle level at the
nd-diastolic phase. The infarct wall was identified as
he area of reduced wall motion (akinetic region).
nfarct wall length was measured as the endocardial
ength of the akinetic region and expressed as a
ercentage of the LV circumference. Infarct wall
hickness (in mm) was measured across the center of
he infarct. Because all animals were pre-selected for
imilar infarct sizes, the relative group differences
easured were not likely due to pre-existing differ-
nces in the dimensions of individual infarcts.
uantiﬁcation of blood vessel density. Mean vascular
ensity per 0.2 mm2 was quantified immunohisto-
hemically (Factor VIII- or alpha-smooth muscle
ctin [SMA]–positive structures) in the infarct region
identified using hematoxylin and eosin staining for
b
s
U
Q
l
fi
I
i
a
A
t
3
V
b
Q
H
w
c
q
R
a
s
c
l
(
C
S
s
S
l
c
l
w
a
i
v
t
t
p
f
s
s
R
E
y
l
c
D
d
h
s
c
t
m
t
f
M
e
1
w
g
(
(
l
g
g
d
a
P
d
e
b
f
t
o
r
g
r
V
d
fi
s
t
p
e
(
V
r
t
b
0
g
a
(
V
i
m
i
s
r
V
r
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 7 , 2 0 0 9
J U L Y 2 0 0 9 : 8 6 9 – 7 9
Fujii et al.
Post-MI Gene Delivery by UTMD in Mice
872asic histological structures on the preceding serial
ection) of heart sections obtained at 14 days after
TMD, as detailed in the Online Appendix (15).
uantiﬁcation of myocardial VEGF and SCF protein
evels. VEGF and SCF protein levels were quanti-
ed (using Western blot analysis or a Mouse SCF
mmunoassay kit, respectively) separately in the
nfarct and remote regions of LV samples collected
t 14 days after UTMD, as detailed in the Online
ppendix. The VEGF levels were normalized to
he levels of housekeeping protein glyceraldehyde
-phosphate dehydrogenase and expressed as
EGF/glyceraldehyde 3-phosphate dehydrogenase
and intensity ratios.
uantiﬁcation of progenitor cells in the myocardium.
eart samples collected at 5 days after UTMD were
ashed, minced into fine pieces, and digested in 0.2%
ollagenase solution. Flow cytometry was used to
uantify the number of VEGF receptor 2 (VEGF-
2)– and c-kit–expressing cells using anti–VEGF-R2
nd anti–c-kit antibodies (BD Biosciences, Missis-
auga, Ontario, Canada). After immunolabeling, the
ells were fixed with 2% paraformaldehyde and ana-
yzed using a Cytomics FC500 MPL flow cytometer
Beckman Coulter Inc., Fullerton, California) with
XP acquisition FC500 software.
tatistical analyses. Data are expressed as mean 
tandard error. Analyses were performed using
PSS software version 12.0, with the critical alpha
evel set at p 0.05. Statistical tests were as follows:
omparisons between 2 groups (VEGF or SCF
evels, VEGF-R2– or c-kit–positive cell counts)
ere made using Student t tests. Comparisons
mong 3 groups (vascular density, cardiac function,
nfarct size) were made using 1-way analyses of
ariance. Repeated measures analyses of variance
ested the main effects and interactions of gene
reatment and time after UTMD on myocardial
erfusion (rise intensity, intensity ratio) and cardiac
unction (%FAC, %EF). When F values were
ignificant, differences between the groups were
pecified with Tukey’s multiple comparison post-tests.
E SULTS
fﬁciency of plasmid DNA delivery. An in vitro anal-
sis performed by separating the microbubble and
iquid phases of the mixture before injection indi-
ated that 72.7  10.8% (n  5) of total plasmid
NA was contained in the microbubble layer. Five
ays after UTMD, GFP expression identified in the
earts of mice that received microbubble/plasmid
olution containing the GFP gene confirmed suc- (essful in vivo transfection using the microbubble
echnique (Fig. 1) Using this approach, we deter-
ined that the plasmid was able to enter cells (with
he assistance of ultrasound energy) and induce
unctional gene expression in the target tissue.
yocardial VEGF and SCF protein levels. Myocardial
xpression levels of VEGF and SCF were quantified
4 days after UTMD. VEGF protein levels in the
hole heart and the infarct region (n  7 for control
roup, n  7 for VEGF) were significantly greater
p  0.05) in the VEGF than in the control group
Fig. 2), and whole heart and remote region SCF
evels (n  7 for control group, n  9 for SCF) were
reater (p  0.05) in the SCF than in the control
roup (Fig. 3). Interestingly, VEGF was most abun-
ant in the infarct region, whereas SCF was most
bundant in the remote region of the heart.
rogenitor cell recruitment to the treated hearts. Five
ays after UTMD, VEGF-R2– and c-kit–
xpressing cells were quantified in the treated hearts
y flow cytometry (n  5 for control group, n  7
or VEGF, n  7 for SCF). In VEGF- or SCF-
reated hearts, the increased myocardial expression
f VEGF or SCF was associated with a greater
ecruitment to the heart (compared with control
roup) of VEGF-R2– or c-kit–expressing cells,
espectively (p  0.05 for both groups) (Fig. 4).
ascular density and myocardial perfusion. Fourteen
ays after UTMD, vascular structures were identi-
ed in the infarct region by immunohistochemical
taining using antibodies against -SMA (to iden-
ify the smooth muscle coating of arterioles, n  5
er group) and Factor VIII (to identify all
ndothelium-lined structures, n  5 per group)
Figs. 5A and 5B). More -SMA– and Factor
III–positive structures were observed in the infarct
egion of VEGF- and SCF-treated hearts than in
hose of control hearts (p  0.01). Surprisingly,
oth types of structures were most abundant (p 
.01) in the SCF group (compared with the VEGF
roup) (Figs. 5C and 5D).
Left ventricular myocardial perfusion was evalu-
ted by MCE before and 14 days after UTMD
n  9 for control group, n  10 per group for
EGF, SCF) (Fig. 6). We observed a significant
nteraction effect (p  0.01) between gene treat-
ent and time after UTMD. In agreement with the
mmunohistochemical data, myocardial rise inten-
ity, which represents blood flow velocity, increased
emarkably in the SCF group (p  0.01 relative to
EGF and control groups). Intensity ratios, which
epresent blood flow volume, increased significantly
p  0.01) in both VEGF and SCF groups com-
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873Figure 1. Efﬁciency of In Vivo Gene Transfection by UTMD
Representative confocal microphotographs illustrating immunostaining with an antibody against green ﬂuorescent protein (GFP, green),
nuclear staining (Hoechst, blue) and the merged images, 5 days after ultrasound-targeted microbubble destruction (UTMD) in the myo-
cardial tissue of mice that received empty plasmids (control group, A to C) or GFP delivery (GFP group, D to I). Arrows in G to I  cells
colocalizing GFP and Hoechst. Magniﬁcation 400 in A to F. Framed areas in D to F are shown enlarged at 600 in G to I.Figure 2. Myocardial VEGF Protein Levels
(A) Myocardial vascular endothelial growth factor (VEGF)165 (and glyceraldehyde 3-phosphate dehydrogenase [GAPDH], control) protein
levels quantiﬁed using Western blot at 14 days after ultrasound-targeted microbubble destruction in the infarct and remote myocardial
regions of mice transfected with VEGF or empty plasmid (control group). (B to D) Quantiﬁcation of VEGF165 levels (VEGF/GAPDH band
intensity ratios) in the infarct (B) and remote (C) regions and in the whole heart (D) of mice in the VEGF and control groups. *p  0.05.
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874ared with the control group, but again, the im-
rovement was significantly greatest in the SCF
roup (p  0.01 relative to the VEGF group).
ardiac function and infarct morphometry. Cardiac
unction (n  10 per group) was evaluated by
chocardiography before and 14 days after UTMD
7 and 21 days after MI). We monitored heart rate
n all animals at both time points and recorded no
ignificant differences among groups or between
Figure 3. Myocardial SCF Protein Levels
Myocardial stem cell factor (SCF) protein expression was quantiﬁed
targeted microbubble destruction in the infarct and remote myocar
group). (A to C) Graphs illustrate SCF levels (expressed in pg/mg) in
mice in the SCF and control groups. *p  0.05.
Figure 4. Progenitor Cell Recruitment to the Treated Hearts
Quantiﬁcation of vascular endothelial growth factor receptor 2 (VEG
centages of total cells) at 5 days after ultrasound-targeted microbu
VEGF (A), stem cell factor (SCF) (B), or empty plasmid (control grou
VEGF-R2– (A) or c-kit– (B) positive cells versus forward scatter are preseime points (mean heart rates in beats/min: control
roup  199  17 at day 0, 245  11 at day 14;
EGF  251  29 at day 0, 230  20 at day 14;
CF  225  16 at day 0, 254  43 at day 14).
efore UTMD therapy, measures of systolic func-
ion (%FAC, %EF) were similar among the 3
roups. However, we observed a significant inter-
ction effect (p 0.01) between gene treatment and
ime after UTMD. Whereas %FAC and %EF
g a mouse SCF immunoassay kit at 14 days after ultrasound-
regions of mice transfected with SCF or empty plasmid (control
infarct (A) and remote (B) regions and in the whole heart (C) of
2, A) and c-kit (B) positive () progenitor cells (expressed as per-
destruction in the myocardial tissue of mice transfected with
eart samples were analyzed using ﬂow cytometry, and plots ofusin
dial
theF-R
bble
p). Hnted (red dots  progenitor cells). *p  0.05.
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875ecreased over the course of 14 days in the control
roup, significant improvements were registered
ver the same time period in both VEGF (p 0.01
or both measures) and SCF (p  0.05 for %FAC,
 0.01 for %EF) groups relative to the control
roup (Figs. 7A to 7D).
At the end of the study, the control group
xhibited characteristic infarct thinning and expan-
ion (lengthening). We found that infarct wall
engths were preserved in the VEGF and SCF
roups compared with the control group (p  0.01
or both groups), and were further preserved (p 
.01) in the SCF group compared with the VEGF
roup. Both VEGF and SCF groups also exhibited
reater preservation of infarct wall thickness than
he control group (p  0.01 for both groups) (Figs.
E and 7F).
I SCUS S ION
he UTMD technique provides a noninvasive
eans to deliver naked DNA to the heart. In the
resent study, both VEGF and SCF were trans-
erred into the infarcted myocardium, the products
f gene translation were identified, and the elevated
Figure 5. Immunohistological Evaluation of Arteriolar and Capil
(A, B) Representative micrographs (low magniﬁcation, with areas of
immunostaining with antibodies against -smooth muscle actin (-
at 14 days after ultrasound-targeted microbubble destruction in the
with empty plasmid (control group) (A, B: i to ii), vascular endothe
(A, B: v to vi). (C to D) Quantiﬁcation of arteriolar (C) and capillary
0.01 versus all groups; #p  0.001 versus control group; †p  0.001rotein levels were associated with improved perfu- aion, greater vascular density, and enhanced cardiac
unction after an MI.
After encouraging pre-clinical studies of angio-
enic gene therapy, clinical trials produced disap-
ointing results (20,21), possibly due to incomplete
r inaccurate gene delivery. Early clinical trials of
ell transplantation demonstrated improved perfu-
ion (1), but limited cell survival may have dimin-
shed the benefits of this approach for cardiac
estoration. UTMD is a noninvasive, targeted de-
ivery technique that may induce sufficient angio-
enesis to increase cell engraftment after transplan-
ation. Potentially, infarcted myocardium could be
repared to support the engraftment of injected and
ecruited cells after an MI by pre-treating the
amaged tissue using UTMD gene treatments re-
eated over a 3- to 5-day period.
We used perflutren lipid microbubbles (the con-
rast agent used for MCE) to deliver plasmid DNA
o the myocardium. These microbubbles are elec-
rically neutral in their unmodified state. However,
e demonstrated that diluting the activated micro-
ubbles with PBS (1:1 ratio) generated a net posi-
ive charge in the solution that facilitated DNA
Densities
rest [black boxes] enlarged in adjacent columns) illustrating
, to identify arterioles, A) or Factor VIII (to identify capillaries, B)
arct region of myocardial tissue sections from mice transfected
rowth factor (VEGF) (A, B: iii to iv), or stem cell factor (SCF)
densities in the myocardial infarct regions of all 3 groups. **p 
rsus all groups.lary
inte
SMA
inf
lial g
(D)ttachment to the lipid microbubbles (H. Fujii et
a
w
u
o
t
b
a
t
l
t
U
w
D
t
c
m
f
d
l
e
a
m
t
m
w
f
e
p
a
s
U
p
w
r
f
a
e
r
t
b
m
f
p
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 7 , 2 0 0 9
J U L Y 2 0 0 9 : 8 6 9 – 7 9
Fujii et al.
Post-MI Gene Delivery by UTMD in Mice
876l., unpublished data, 2009). The mechanism by
hich the plasmids bind to the microbubble shell is
nclear and will require a thorough evaluation, but
ur in vitro study indicated that more than 72% of
he plasmid DNA was associated with the micro-
ubbles. Future studies should compare lipid- and
lbumin-based microbubbles to determine the op-
imal type for gene delivery; however, perflutren
ipid microbubbles have a high membrane affinity
hat may facilitate gene transfer (14). In addition,
TMD may induce transient endothelial injury,
hich could facilitate the transit of the plasmid
NA into myocardial tissue (22,23). In our model,
reatment with naked plasmid and UTMD did not
ause a decline in cardiac function, suggesting that
inor injury to the endothelium did not produce a
unctional consequence. The UTMD technique
id, however, induce significant increases in the
evels of GFP, VEGF, and SCF in the gene recipi-
nts. And although additional regional assessments
re required to confirm our results in larger animal
odels because the small rodent model is limited by
Figure 6. Myocardial Perfusion by Myocardial Contrast Echocard
(A) Representative images obtained by myocardial contrast echocar
targeted microbubble destruction in mice transfected with empty p
stem cell factor (SCF). (B) Rise intensity (/ms) assessed as a measure
(C) Myocardial intensity ratios (anterior [ant] wall {infarct} intensity/
of myocardial blood ﬂow volume in all 3 groups at D0 and D14. An
region. **p  0.01.he potential for variations in functional measure- ments, our data suggest that even a single treatment
as sufficient to produce an improvement in global
unction.
Although we did not calculate gene transfection
fficiency in vivo, our studies with GFP-carrying
lasmids allowed us to visualize the cells that
ccepted the delivered gene. We did not determine
pecifically which cell types were transfected by the
TMD technique; however, significant GFP ex-
ression was identified in fibroblasts and within the
alls of blood vessels in both the infarct and remote
egions. These findings suggest that the UTMD
acilitates gene delivery not only to blood vessels but
lso to deeper tissues. It is unclear why SCF
xpression was principally increased in the remote
egion, whereas VEGF was principally increased in
he infarct region, but comparing effects in the
order zone with those in the infarct would allow a
ore precise localization of gene delivery.
Beyond our qualitative evaluation of cardiac per-
usion via contrast echocardiography, we also com-
leted a quantitative immunohistochemical assess-
raphy
raphy performed before (D0) and 14 days (D14) after ultrasound-
id (control group), vascular endothelial growth factor (VEGF), or
myocardial blood ﬂow velocity in all 3 groups at D0 and D14.
erior [post] wall {remote region} intensity) calculated as a measure
rease in this ratio reﬂects increased ﬂow volume in the infarctiog
diog
lasm
of
post
incent of blood vessel density that identified
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877ignificant local effects of VEGF and SCF overex-
ression. These findings are in agreement with our
revious report, in which cells transfected with the
EGF gene promoted angiogenesis after they were
njected into the myocardium (24). Our histological
ndings (-SMA and Factor VIII staining) indi-
ated more vascular structures in the SCF compared
ith the VEGF group; rise intensity was also
ighest in the SCF group. The reason for these
ffects is presently unknown, but suggests a critical
ole for SCF in mediating flow velocity through
rteriogenesis. The effect may be driven by the
ecruited c-kit–expressing cells, which we have
reviously shown are critical to post-MI angiogen-
sis (15). Future studies might include an accurate
haracterization (using multiple surface markers) of
he recruited progenitor cells and their origins and
hould also determine the benefits of combined
ene therapy or the delivery of other genes, such as
broblast growth factor, which might have clinical
tility. In this study, because we administered gene
herapy at 7 days after MI, the improvements in
lobal ventricular function may have been related to
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Figure 7. Cardiac Function and Infarct Morphometry by Echoca
(A) Fractional area change (%FAC, evaluated using the short-axis vi
fraction (%EF, calculated from M-mode data) measured by echocard
microbubble destruction (UTMD) in mice transfected with empty pl
growth factor (VEGF). (C) Changes in %FAC and (D) %EF measured
tional parameters over 14 days after UTMD. (E) Infarct wall length (
ference) and (F) infarct wall thickness (measured at the midpapillar
all 3 groups at 14 days after UTMD. *p  0.05; **p  0.01.he prevention of adverse remodeling. However, pTMDmight effectively be used earlier after MI to
itigate reperfusion injury or rescue myocardial
issue.
To facilitate the delivery of plasmid DNA into
he myocardial tissue, we used a high mechanical
ndex to destroy the microbubbles in an intermit-
ent mode (1 burst  every 4 to 5 heartbeats). This
iming was selected to allow the microbubbles to fill
he capillaries during each pulsing interval and to
inimize endothelial damage during UTMD. Our
esults suggest that these settings were effective for
n vivo gene delivery and produced no obvious
yocardial/endothelial injury by histological or
unctional examination. Additional experiments
ill confirm the optimal concentrations of micro-
ubbles and plasmid DNA for gene delivery and the
ptimal ultrasound settings, and may also examine
he location of the approach’s effects in normal
eart tissue.
The ultrasound settings were adjusted not only to
aximize microbubble destruction but also to op-
imize the evaluation of myocardial perfusion,
hich was accomplished using both early and late
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graphy
t the midpapillary muscle level of the left ventricle). (B) Ejection
raphy before (D0) and 14 days (D14) after ultrasound-targeted
id (control group), stem cell factor (SCF), or vascular endothelial
0 and D14 in all 3 groups to assess the increase in these func-
essed as a percentage of the left ventricular endocardial circum-
scle level short axis view in the center of the infarct) measured inB
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y muhase plateau intensities. We also reduced the risk
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878or endothelial injury (22,23) by maintaining a high
ntensity with a short pulsing interval. Higher
requencies are required for high-quality perfusion
mages, but lower frequencies are required to de-
troy the microbubbles: we therefore used a me-
hanical index of 1.5 to 1.6, which is the highest
etting in clinical use, and set the frequency at 8
Hz, which is the lowest frequency on this trans-
ucer. This combination allowed us to deliver the
enes to the heart and detect significant differences
n perfusion despite variability between groups and
ow signal intensity. Improved echocardiographic
echniques will enhance the quality of the diagnos-
ic images in both small and larger animal models
hile maintaining adequate gene delivery. Quanti-
ative measures of myocardial perfusion will also be
equired before the clinical application of UTMD.
ONCLUS IONS
n summary, we successfully delivered VEGF and
CF genes into the infarcted heart using UTMD.2003;10:285–91. 102–6.ion resulting from vector delivery contributed to
ndogenous VEGF/SCF expression and increased
ngiogenesis, but plasmid delivery was associated
ith significantly greater vascular density, protein
xpression, and progenitor cell homing in gene
ecipients relative to controls, with a net effect of
mproved myocardial perfusion and function. Our
ndings further suggest that the SCF gene plays an
mportant role in arteriogenesis. Perhaps by induc-
ng a greater influx of c-kit–expressing cells than
EGF, SCF may have the greater potential for
yocardial restoration.
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